Market Overview

Navidea to Collaborate with Maimonides Medical Center on Trial Utilizing Lymphoseek for Lymphatic Mapping in Colorectal Cancer

Related NAVB
Navidea Biopharm Enters Agreement With Alseres to Terminate NAV5001 Sub-License Agreement
Morning Market Gainers
As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect From Biotech Next (Seeking Alpha)

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it has entered into an agreement to collaborate with Maimonides Medical Center to investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept) Injection in lymphatic mapping procedures for colorectal cancer. Dr. Danny Sherwinter, surgeon and the Director of the Department of Minimally Invasive & Bariatric Surgery at Maimonides Medical Center in Brooklyn, NY, will lead the investigator-initiated clinical study. This open-label evaluation, expected to start enrollment in early 2013, will be performed at Maimondes and will include the assessment of lymph nodes from up to 40 colon cancer subjects. According to the American Cancer Society, approximately 140,000 new cases of colorectal cancer are expected to be diagnosed in the United States annually^1 while worldwide annual diagnosis is over 1.2 million.

Posted-In: News


Related Articles (NAVB)

Around the Web, We're Loving...